UBS raised the firm’s price target on West Pharmaceutical (WST) to $320 from $285 and keeps a Buy rating on the shares. Growth is getting back on track for West Pharmaceutical, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical Services Reports Strong Q2 2025 Results
- West Pharmaceutical Services’ Earnings Call Highlights Strong Growth
- West Pharmaceutical rises 22.2%
- West Pharmaceutical price target raised to $350 from $275 at Evercore ISI
- Strong Growth Prospects and Margin Recovery Justify Buy Rating for West Pharmaceutical Services